Li-Ping Xie is the chairman of urology department，First Affiliated Hospital, Zhejiang University School of Medicine. During his 30 years’ dedication in urology, he has carried out numerous creati
Li-Ping Xie is the chairman of urology department，First Affiliated Hospital, Zhejiang University School of Medicine. During his 30 years’ dedication in urology, he has carried out numerous creative scientific and clinical research, focusing on urological oncology, minimal invasive surgery and prostate disease, especially in prostate cancer screening, novel therapy towards CRPC and anatomical radical prostatectomy.
1978-1982 Bachelor degree, Zhejiang Medical University, Hangzhou, P.R. China
1985-1988 Master degree, Zhejiang Medical University, Hangzhou, P.R. China
1991-1993 M. D., Kiel University, Kiel, Germany
2001.4-7 Visiting professor, West Virginia University
2004.5 Visiting professor, The University of Southern California/Norris Comprehensive Cancer Center
2004.9 Visiting professor, The Brady Urological Institute of Johns Hopkins Hospital
2007.5 Visiting professor, Massachusetts General Hospital, Harvard University
Chairman, Department of Urology, First Affiliated Hospital, Zhejiang University School of Medicine;
Standing Committee Member of Chinese Urological Association;
Vice-President of Chinese Urological Association;
Standing Committee Member of the Committee of Genitourinary Tumor, Chinese Anti-Cancer Association;
2011-2013 AUA International Member Committee (IMC) representative for China;
Corresponding Member of the European Association of Urology;
National Representative to the Asia-Pacific Society of Uro-oncology (APSU)
Faculty of 2007 WCE Annual Meeting;
Vice-Chairman of Local Organizing Committee of 2008 WCE Annual Meeting;
Scientific Committee Member of 2009 SIU Annual Congress;
Co-Chair of 2009-2013 EAU-CUA Joint Session of EAU Annual Congress;
Publications in recent years
1. miR-26a inhibits proliferation and motility in bladder cancer by targeting HMGA1. FEBS Lett. 2013 Aug 2;587(15):2467-73. Lin Y, Chen H, Hu Z, Mao Y, Xu X, Zhu Y, Xu X, Wu J, Li S, Mao Q, Zheng X, Xie L*.
2. Promoter-targeted double-stranded small RNAs activate PAWR gene expression in human cancer cells. Int J Biochem Cell Biol. 2013 Jul;45(7):1338-46. Yang K, Shen J, Xie YQ, Lin YW, Qin J, Mao QQ, Zheng XY, Xie LP*
3. MicroRNA-409-3p inhibits migration and invasion of bladder cancer cells via targeting c-Met. Mol Cells. 2013 Jul;36(1):62-8. Xu X, Chen H, Lin Y, Hu Z, Mao Y, Wu J, Xu X, Zhu Y, Li S, Zheng X, Xie L*.
4. Apigenin promotes apoptosis, inhibits invasion and induces cell cycle arrest of T24 human bladder cancer cells. Cancer Cell Int. 2013 Jun 1;13(1):54. Zhu Y, Mao Y, Chen H, Lin Y, Hu Z, Wu J, Xu X, Xu X, Qin J, Xie L*.
5. No association between tea consumption and risk of renal cell carcinoma: a meta-analysis of epidemiological studies. Asian Pac J Cancer Prev. 2013;14(3):1691-5. Hu ZH, Lin YW, Xu X, Chen H, Mao YQ, Wu J, Xu XL, Zhu Y, Li SQ, Zheng XY, Xie LP*.
6. Genetic polymorphisms of glutathione S-transferase M1 and prostate cancer risk in Asians: a meta-analysis of 18 studies. Asian Pac J Cancer Prev. 2013;14(1):393-8. Hu ZH, Lin YW, Xu X, Chen H, Mao YQ, Wu J, Zhu Y, Xu XL, Xie LP*.
7. MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met. Biochem Biophys Res Commun. 2013 May 24;435(1):82-7. Hu Z, Lin Y, Chen H, Mao Y, Wu J, Zhu Y, Xu X, Xu X, Li S, Zheng X, Xie L*.
8. Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. PLoS One. 2013;8(3):e58079. Xu X, Wu J, Mao Y, Zhu Y, Hu Z, Xu X, Lin Y, Chen H, Zheng X, Qin J, Xie L*.
9. Quantitative assessment of the associations between XRCC1 polymorphisms and bladder cancer risk. World J Surg Oncol. 2013 Mar 7;11:58. Mao Y, Xu X, Lin Y, Chen H, Wu J, Hu Z, Zhu Y, Xu X, Xie L.
10. Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells. World J Surg Oncol. 2013 Jan 28. Zhu HB, Yang K, Xie YQ, Lin YW, Mao QQ, Xie LP*.
11. A meta-analysis of tea consumption and the risk of bladder cancer. Urol Int. 2013;90(1):10-6. Wang X, Lin YW, Wang S, Wu J, Mao QQ, Zheng XY, Xie LP*.
12. PAI-1 promoter 4G/5G polymorphism (rs1799768) contributes to tumor susceptibility: Evidence from meta-analysis. Exp Ther Med. 2012 Dec;4(6):1127-1133. Xu X, Xie Y, Lin Y, Xu X, Zhu Y, Mao Y, Hu Z, Wu J, Chen H, Zheng X, Qin J, Xie L*.
13. Epigallocatechin-3-gallate inhibits bladder cancer cell invasion via suppression of NF-κB‑mediated matrix metalloproteinase-9 expression. Mol Med Rep. 2012 Nov;6(5):1040-4. Qin J, Wang Y, Bai Y, Yang K, Mao Q, Lin Y, Kong D, Zheng X, Xie L*.
14. Body mass index and risk of BPH: a meta-analysis. Prostate Cancer Prostatic Dis. 2012 Sep;15(3):265-72. Wang S, Mao Q, Lin Y, Wu J, Wang X, Zheng X, Xie L*.
15. Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of prostate cancer in the Han population of China. Med Oncol. 2012 Sep;29(3):1964-71. Wang X, Wang S, Lin YW, Wu J, Chen H, Mao YQ, Zheng XY, Zhou C, Xie LP*.
16. Association of vitamin D receptor gene polymorphism and calcium urolithiasis in the Chinese Han population. Urol Res. 2012 Aug;40(4):277-84. Wang S, Wang X, Wu J, Lin Y, Chen H, Zheng X, Zhou C, Xie L*.
17. MicroRNA-449a acts as a tumor suppressor in human bladder cancer through the regulation of pocket proteins. Cancer Lett. 2012 Jul 1;320(1):40-7. Chen H, Lin YW, Mao YQ, Wu J, Liu YF, Zheng XY, Xie LP*.
18. Upper urinary tract inverted papillomas: Report of 10 cases. Oncol Lett. 2012 Jul;4(1):71-74. Luo JD, Wang P, Chen J, Liu B, Wang S, Shen BH, Xie LP*.
19. Prostate Cancer Risk in Relation to a Single Nucleotide Polymorphism in the Insulin-like Growth Factor-binding Protein-3 (IGFBP3) Gene: a Meta-analysis. Asian Pac J Cancer Prev. 2012;13(12):6299-303. Mao YQ, Xu X, Lin YW, Chen H, Hu ZH, Xu XL, Zhu Y, Wu J, Zheng XY, Qin J, Xie LP*.
20. Cyclin-dependent kinase 4 is a novel target in micoRNA-195-mediated cell cycle arrest in bladder cancer cells. FEBS Lett. 2012 Feb 17;586(4):442-7. Lin Y, Wu J, Chen H, Mao Y, Liu Y, Mao Q, Yang K, Zheng X, Xie L*.
21. Transurethral vapor enucleation and resection of the prostate with plasma vaporization button electrode for the treatment of benign prostatic hyperplasia: a feasibility study. J Endourol. 2012 Oct;26(10):1264-6. Xie L*, Mao Q, Chen H, Qin J, Zheng X, Lin Y, Wang X, Liu B.
1. A new nephroprotective amino acid mixture.
2. Bladder manipulator used in laparoscopy.
3. Multichannel laporoscopic trocar.
4. Support devices for laparoscopic surgeries.
5. Separator for extraperitoneal space in laparoscopic surgeries.
6. Mushroom-like temporary stent for prostate.
7. Trocar for percutaneous resection of bladder tumor.
8. Balloon temporary stent for prostate.
9. Deflectable device for laparoscopic surgeries.
10. Balloon-tipped intravesical slow-release capsule.